A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.

Cancer
Greg DurmNasser Hanna

Abstract

Five-year overall survival (OS) for patients with unresectable stage III non-small cell lung cancer (NSCLC) is poor. Until recently, a standard of care was concurrent chemoradiation alone. Patients with metastatic NSCLC treated with anti-programmed death 1 antibodies have demonstrated improved OS. This trial evaluated pembrolizumab as consolidation therapy after concurrent chemoradiation in patients with unresectable stage III disease. Patients with unresectable stage III NSCLC received concurrent chemoradiation with cisplatin and etoposide, cisplatin and pemetrexed, or carboplatin and paclitaxel and 59.4 to 66.6 Gy of radiation. Patients with nonprogression of disease were enrolled and received pembrolizumab (200 mg intravenously every 3 weeks for up to 12 months). The primary endpoint was the time to metastatic disease or death (TMDD). Secondary endpoints included progression-free survival (PFS) and OS. The median follow-up for 93 patients (92 for efficacy) was 32.2 months (range, 1.2-46.6 months). The median TMDD was 30.7 months (95% confidence interval [CI], 18.7 months to not reached), which was significantly longer than the historical control of 12 months (P < .0001). The median PFS was 18.7 months (95% CI, 12.4-33.8 mont...Continue Reading

References

Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chandra P BelaniWalter J Curran
Apr 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Everett E VokesUNKNOWN Cancer and Leukemia Group B
Apr 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karen KellyDavid R Gandara
Nov 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R SpigelF Anthony Greco
Mar 31, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne AupérinJean-Pierre Pignon
May 28, 2010·Journal of the National Cancer Institute·Charles LuMichael J Fisch
Jan 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tien HoangDavid H Johnson
Jul 26, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kazuyuki TsujinoMasahiko Ando
Jan 3, 2014·The Journal of Clinical Investigation·Liufu DengYang-Xin Fu
Sep 5, 2014·Cancer Immunology Research·Chad TangJames W Welsh
Dec 17, 2014·Frontiers in Oncology·Ralph E VatnerSilvia C Formenti
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Sep 9, 2017·The New England Journal of Medicine·Scott J AntoniaUNKNOWN PACIFIC Investigators
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Oct 4, 2018·The New England Journal of Medicine·Scott J AntoniaUNKNOWN PACIFIC Investigators

❮ Previous
Next ❯

Citations

Dec 15, 2020·World Journal of Clinical Oncology·Xabier Mielgo-RubioFelipe Couñago
May 11, 2021·Frontiers in Oncology·Jonathan KhalifaElizabeth Cohen-Jonathan Moyal
May 18, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Francesco PassigliaSilvia Novello
Jul 9, 2021·Lung Cancer : Targets and Therapy·Nikhil Shukla, Nasser Hanna

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.